{"slideshow_credits": null, "snippet": "The decision went against the recommendation of independent experts, and the agency is requiring an additional trial to confirm effectiveness....", "abstract": "Food and Drug Administration approves eteplirsen, medication for Duchenne muscular dystrophy, overriding objections by their own experts and bowing to intense patient lobbying; vote leads stock of drug maker Sarepta Therapeutics to soar. ", "section_name": "Business Day", "print_page": "1", "document_type": "article", "byline": {"person": [{"firstname": "Sabrina", "role": "reported", "lastname": "TAVERNISE", "rank": 1, "organization": ""}], "original": "By SABRINA TAVERNISE"}, "web_url": "http://www.nytimes.com/2016/09/20/business/fda-approves-muscular-dystrophy-drug-that-patients-lobbied-for.html", "lead_paragraph": "The decision went against the recommendation of independent experts, and the agency is requiring an additional trial to confirm effectiveness.", "headline": {"main": "F.D.A. Approves Muscular Dystrophy Drug That Patients Lobbied For", "print_headline": "F.D.A. Clears Debated Drug That Patients Lobbied For"}, "_id": "57e05a7b95d0e021d7987280", "word_count": "747", "multimedia": [{"height": 126, "url": "images/2016/09/20/business/20DRUG/20DRUG-thumbWide.jpg", "legacy": {"wideheight": "126", "wide": "images/2016/09/20/business/20DRUG/20DRUG-thumbWide.jpg", "widewidth": "190"}, "subtype": "wide", "width": 190, "type": "image"}, {"height": 400, "url": "images/2016/09/20/business/20DRUG/20DRUG-articleLarge.jpg", "legacy": {"xlarge": "images/2016/09/20/business/20DRUG/20DRUG-articleLarge.jpg", "xlargewidth": "600", "xlargeheight": "400"}, "subtype": "xlarge", "width": 600, "type": "image"}, {"height": 75, "url": "images/2016/09/20/business/20DRUG/20DRUG-thumbStandard.jpg", "legacy": {"thumbnail": "images/2016/09/20/business/20DRUG/20DRUG-thumbStandard.jpg", "thumbnailwidth": "75", "thumbnailheight": "75"}, "subtype": "thumbnail", "width": 75, "type": "image"}], "pub_date": "2016-09-20T04:00:00+0000", "source": "The New York Times", "news_desk": "Business", "keywords": [{"name": "subject", "value": "Muscular Dystrophy", "is_major": "Y", "rank": "1"}, {"name": "organizations", "value": "Food and Drug Administration", "is_major": "Y", "rank": "2"}, {"name": "organizations", "value": "Sarepta Therapeutics Inc.", "is_major": "Y", "rank": "3"}, {"name": "subject", "value": "Clinical Trials", "is_major": "N", "rank": "4"}, {"name": "subject", "value": "Drugs (Pharmaceuticals)", "is_major": "Y", "rank": "5"}], "blog": [], "subsection_name": null, "type_of_material": "News"}